So, just out of curiosity, how might this new COVID related pediatric Kawasaki indication play out with Leronlimab?

Would the FDA require a whole new multi-phase trial to determine safety, dosage, efficacy with children?

Fortunately, this syndrome still seems relatively rare so far, so I'm not sure how many young patients would be available for trials even if they were required.